株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

角膜炎:パイプライン製品の分析

Keratitis - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 200462
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.76円で換算しております。
Back to Top
角膜炎:パイプライン製品の分析 Keratitis - Pipeline Review, H2 2017
出版日: 2017年10月31日 ページ情報: 英文 59 Pages
概要

角膜炎とは角膜の炎症です。症状としては、眼の充血、眼痛、視覚低下(かすみ目)、視力低下、光に対する過敏症などが現れます。 危険因子として、ウィルス感染、けが、気候条件、免疫力の低下などが挙げられます。

当レポートでは、角膜炎の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

角膜炎 - 概要

角膜炎 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

角膜炎 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

角膜炎の治療薬開発に従事している企業

  • Adamis Pharmaceuticals Corp
  • Dompe Farmaceutici SpA
  • Editas Medicine Inc
  • EyeGate Pharmaceuticals Inc
  • NanoViricides Inc
  • RegeneRx Biopharmaceuticals Inc
  • SIFI SpA
  • The Medicines Company

薬剤プロファイル

角膜炎 - 休止中のプロジェクト

角膜炎 - 開発が中止された製品

角膜炎 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9839IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H2 2017, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Keratitis - Overview
    • Keratitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Keratitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Keratitis - Companies Involved in Therapeutics Development
    • Adamis Pharmaceuticals Corp
    • Editas Medicine Inc
    • EyeGate Pharmaceuticals Inc
    • MimeTech Srl
    • NanoViricides Inc
    • RegeneRx Biopharmaceuticals Inc
    • SIFI SpA
    • The Medicines Company
    • Keratitis - Drug Profiles
    • acyclovir sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • B-2088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-31G - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Herpetic Keratitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IVMED-90 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JDE-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KU-55933 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PIM-45 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polihexanide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGN-259 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Herpetic Keratitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DNA Synthesis for Herpetic Keratitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • targocil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tigecycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBP-245 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Z-9445 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Keratitis - Dormant Projects
  • Keratitis - Discontinued Products
  • Keratitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China
      • May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease
      • Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday
      • Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials
      • Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial
      • Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259
      • Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Keratitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Keratitis - Pipeline by Adamis Pharmaceuticals Corp, H2 2017
  • Keratitis - Pipeline by Editas Medicine Inc, H2 2017
  • Keratitis - Pipeline by EyeGate Pharmaceuticals Inc, H2 2017
  • Keratitis - Pipeline by MimeTech Srl, H2 2017
  • Keratitis - Pipeline by NanoViricides Inc, H2 2017
  • Keratitis - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017
  • Keratitis - Pipeline by SIFI SpA, H2 2017
  • Keratitis - Pipeline by The Medicines Company, H2 2017
  • Keratitis - Dormant Projects, H2 2017
  • Keratitis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Keratitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top